Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06287580
Other study ID # STU-2024-0140
Secondary ID
Status Not yet recruiting
Phase Early Phase 1
First received
Last updated
Start date May 15, 2024
Est. completion date January 1, 2027

Study information

Verified date April 2024
Source University of Texas Southwestern Medical Center
Contact TAKURO WASHIO, Ph.D.
Phone 214-345-4852
Email TakuroWashio@texashealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High blood pressure (BP) is a public health problem worldwide. Nearly three-quarters of older adults (age ~60 years) in the United States have high BP. High BP links to many health problems, like stroke. Drug treatments are typically used in clinics to reduce high BP and the risk of associated health problems. However, these drug treatments may not always benefit brain health. For example, drug treatment may reduce brain blood flow, which may reduce cognitive function in older adults with high BP. Alternatively, reduced brain blood flow may cause high BP due to increased nervous system activity (the so-called "fight or flight response"). Thus, monitoring brain blood flow may help to manage high BP during drug treatment. It is unknown if brain blood flow and its control will be altered by drug treatment in older high BP patients. Therefore, study team will recruit older adults with high BP, who receive either drug treatment or a placebo for 2 weeks and will assess brain blood flow, cognitive function, and nervous system control before and after treatment. Results from this study will provide novel and clinically relevant information on the impact of drug treatment for high BP on brain health. Investigators expect these results will suggest that it is crucial to measure brain blood flow, which may be a therapeutic new target for BP control and brain health.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date January 1, 2027
Est. primary completion date January 1, 2026
Accepts healthy volunteers No
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: - Older men and women with mild-to-moderate essential hypertension (60-85 years, clinic systolic BP 130-159 and/or diastolic BP 80-109 mmHg) Exclusion Criteria: - Any evidence of cardiovascular or pulmonary disease by medical history or by physical examination - Severe hypertension (systolic BP =160 and/or diastolic BP =110 mmHg; for safety reasons) or secondary hypertension - Being on =3 antihypertensive agents - Chronic kidney disease (an estimated glomerular filtration rate >45 mL/min) or renal failure - Diabetes mellitus (fasting glucose =126 mg/dL or 2-hour oral glucose tolerance test, glucose level =200 mg/dL) or other systemic illness - Any history of substance abuse (other than tobacco) - Current cigarette smokers - History of gouty arthritis - Taking hormonal replacement therapy - Endurance-trained athletes - Diagnosed Alzheimer's disease and related dementias

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
chlorthalidone 25 mg
chlorthalidone, 25 mg orally once daily
Other:
Placebo
Placebo tablet taken orally once daily

Locations

Country Name City State
United States Institute for Exercise and Environmental Medicine Dallas Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Muscle sympathetic nerve activity (MSNA) from baseline at 2 weeks post intervention Muscle sympathetic nerve activity will be measured using microneurography at the peroneal nerve. Muscle sympathetic nerve activity will be quantified by identification and measurement of sympathetic bursts in the integrated neurogram and expressed as burst frequency (mean number of bursts per unit time) Baseline, 2 weeks post intervention
Primary Change in cognitive performance from baseline at 2 weeks post intervention via Stroop Color and Word Test Change in cognitive performance is measured by Stroop Color and Word Test. Accuracy and reaction time in the Stroop Color and Word test are computed to assess cognitive performance. Baseline, 2 weeks post intervention
Primary Change in cognitive performance from baseline at 2 weeks post intervention via NIH Toolbox Cognitive Battery Change in cognitive performance is measured by NIH Toolbox Cognitive Battery that yields individual test scores and the following summary scores: Total Cognition Composite, Fluid Composite (includes Dimensional Change Card Sort, Flanker Inhibitory Control and Attention, Picture Sequence Memory, List Sorting Working Memory, and Pattern Comparison tests), and Crystallized Composite (includes Picture Vocabulary and Oral Reading Recognition tests). The NIH Toolbox Cognitive Battery results convert to uncorrected standard scores (mean±standard deviation, 100±15), where higher indicate better outcome. Baseline, 2 weeks post intervention
Primary Change in Cerebral blood flow from baseline at 2 weeks post intervention A probe will be placed over an artery in participant's neck and temple. Total cerebral blood flow is calculated as a sum of blood flow from the four arteries of the internal carotid artery and vertebral artery. The distribution of cardiac output to the brain is calculated as the percentage of total cerebral blood flow to cardiac output. Baseline, 2 weeks post intervention
See also
  Status Clinical Trial Phase
Recruiting NCT03708601 - Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Not yet recruiting NCT05503953 - Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS Phase 3
Recruiting NCT05526703 - Clinical Trial to Evaluate the Efficacy and Safety of D064 and D701 Combination Therapy Phase 3
Completed NCT06395194 - Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension Phase 3
Not yet recruiting NCT06418074 - Effects of Exogenous Ketosis on Renal Function, Renal Perfusion, and Sodium Excretory Capacity N/A
Completed NCT02890173 - Study of CS-3150 in Patients With Essential Hypertension Phase 3
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Completed NCT02944734 - Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension Phase 2
Recruiting NCT01956786 - Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine Phase 2/Phase 3
Completed NCT02553512 - Helius in Hypertension-I: The UK Hypertension Registry N/A
Completed NCT01198249 - Pharmacokinetic Drug Interactions Between Single and Concomitant Administrations of Amlodipine, Losartan, and Hydrochlorothiazide in Subjects With (Pre)Hypertension Phase 1
Completed NCT01001572 - Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension Phase 3
Recruiting NCT00380289 - Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension N/A
Completed NCT00139698 - Olmesartan Alone or in Combination With Hydrochlorothiazide in Subjects With Mild to Moderate Essential Hypertension Phase 3
Completed NCT00288184 - Uric Acid in Essential Hypertension in Children Phase 2
Completed NCT01289886 - Fimasartan (BR-A-657) Single Oral Dose in Healthy Subjects Phase 1
Not yet recruiting NCT06041529 - Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension Phase 4
Completed NCT04470830 - A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
Completed NCT00758524 - A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension Phase 2
Recruiting NCT05109013 - Juvenile Essential Arterial Hypertension and Vascular Function